Evidence map›Paper›PMID 42684842›Full record

ReviewWomen's health (London, England)

Optimisation of maternal cardiometabolic outcomes after hypertensive disorders of pregnancy.

Hua Zen Ling, Mark Johnson

Abstract readReview
In one paragraph

Review in Women's health (London, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hua Zen LingImperial College London, London, UK.ORCID 0000-0002-6857-9990
Mark JohnsonImperial College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Women with pregnancies complicated by hypertensive disorders of pregnancy (HDP) are at significantly increased risk of cardiovascular (CVD) and metabolic diseases. Current international guidelines acknowledge this risk, however the timing, duration and method of CV screening in these high-risk women remain heterogenous. There remains a lack of an evidenced-based approach to the transition of care from hospital to community and longer-term cardiac-metabolic disease prevention.This narrative review examines the optimal timing and duration of cardiometabolic surveillance after delivery, approaches to risk stratification to identify women at greatest risk of future cardiovascular morbidity, and strategies for screening myocardial, vascular, and metabolic health. This review also explores how limited postpartum healthcare resources may be targeted most effectively, with particular emphasis on the transition from hospital to community care during the "fourth trimester" and interventions that promote sustained engagement in long-term behavioural and lifestyle modification.Current evidence supports the potential role of multidisciplinary postpartum cardiovascular clinics in delivering coordinated, risk-stratified care following HDP. These clinics facilitate early optimisation of BP through telemonitoring and patient-led medication titration, while integrating lifestyle interventions tailored to PE phenotypes and individual CV risk profiles. Future research should focus on validated risk stratification tools to identify and personalise postpartum interventions to women who are most at risk of CV morbidities. This should include risk prediction, targeted interventions based on risk profiles, and integrated care pathways in the community to optimise long-term maternal CV outcomes.

Indexed as

Cardiovascular DiseasesHypertension, Pregnancy-InducedMetabolic DiseasesFemaleHumansPostpartum PeriodPregnancyRisk AssessmentRisk Factorscardiac remodellingcardiovascular disease in womencardiovascular riskhypertensive pregnancy disordersmetabolicpostpartumpreeclampsiapreventionvascular

Identifiers

PMID42684842
PMCPMC13538997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.